NCI R50 Clinician Scientist Award

NCI R50 临床科学家奖

• 批准号: 10569255
• 负责人: Brian A. Jonas
• 金额: $ 8.67万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10569255
• 关键词: Acute Lymphocytic Leukemia; Acute leukemia; American College of Radiology Imaging Network; Award; Biological Markers; California; Cancer Therapy Evaluation Program; Clinical; Clinical Research; Clinical Treatment; Clinical Trials; Clinical Trials Network; Clinical Trials Unit; Complement; Comprehensive Cancer Center; Data; Dedications; Detection; Development; Disease; Doctor of Philosophy; Dysmyelopoietic Syndromes; Eastern Cooperative Oncology Group; Educational process of instructing; Growth; Hematologic Neoplasms; Hematology; Heme; Individual; Institution; Investigational Therapies; Leadership; Malignant Neoplasms; Monitor; National Clinical Trials Network; Oncology; Oncology Group; Participant; Patients; Prevention; Productivity; Qualifying; Research; Safety; Scientist; Services; Shapes; Southwest Oncology Group; Specialist; Therapeutic; Time; Training; cancer care; cancer clinical trial; cancer therapy; clinical trial implementation; design; improved; leukemia; leukemic stem cell; member; mid-career faculty; multidisciplinary; novel; programs; therapeutic target; translational study; working group

ABSTRACT/SUMMARY NCI clinical trials networks are essential to strengthen the cancer care of the nation by expediting the discovery of novel cancer treatments and therapeutic strategies. Central to this effort are the clinician scientists who development, implement, manage, and provide oversight to these individual trials and trial networks. While essential, these clinicians are frequently tasked with significant clinical, administrative, and teaching responsibilities that may inhibit substantiative contribution to NCI-sponsored clinical trial activity. The R50 Research Specialist /Clinician Scientist Award is designed to protect time and allow the clinician scientist to significantly contribute to NCI-sponsored clinical trials and NCI clinical trials networks through leadership in the development of national clinical trials, implementation of NCI clinical trials in their institutions, and national service to the NCI clinical trials networks. Dr. Brian Jonas, MD, PhD, is a leukemia specialist and an Associate Professor within the Department of Hematology/Oncology at UC Davis Comprehensive Cancer Center (UCDCCC). As an active and highly dedicated clinical scientist and trialist at UC Davis, he has established himself as a leader in opening clinical trials for the treatment of AML, MDS, acute lymphoblastic leukemia (ALL) and other hematologic malignancies. Moreover, he has received the coveted “Top Accrurer” Award within the cancer clinical trials unit. His clinical research is complemented by his translational studies involving AML biomarkers, chemosensitivity and therapeutic targeting of leukemia stem cells. As an asset to UCDCCC, he has served as PI on several clinical trials and as a leader in clinical trials management. This includes chairing the UCDCCC Hematologic Malignancies Disease Team Committee and the UCDCCC Data and Safety Monitoring Committee. In addition to his contributions at UC Davis, Dr. Jonas has contributed to multidisciplinary clinical and translational teams such as the Leukemia Committee and Working Group for the Southwest Oncology Group (SWOG), and the Calif ornia Cancer Consortium to shape and inf orm clinical trial portf olios at the UCDCCC, the National Clinical Trials Network (NCTN) and the Experimental Therapeutics Clinical Trials Network (ET-CTN). This includes his service as national chair of two ECTCN trials developed through the CTEP Project Team mechanism and the SWOG champion for an ECOG-ACRIN AML trial in development through the NCTN. He is also an active participant in the UM1 Consortium, the California Cancer Consortium (CCC), and a member of the CCC Heme Working Group. Overall, Dr. Jonas is a well-qualified clinician scientist candidate for the NCI R50 Research Specialist Award and has demonstrated prior and continuing leadership in the development of national clinical trials, implementation of NCI-sponsored clinical trials at UCD, and service to NCI clinical trial networks through participation in our CCC. The R50 award will facilitate continued growth of his research program and advancement of his institutional and national leadership.

摘要/总结 NCI 临床试验网络对于通过加快发现速度来加强国家癌症护理至关重要 这项工作的核心是临床科学家。 开发、实施、管理和监督这些单独的试验和试验网络。 至关重要的是，这些指挥官经常承担重要的临床、行政和教学任务 可能会抑制对 NCI 资助的临床试验活动做出实质性贡献的责任。 研究专家/临床科学家奖旨在保护时间并允许临床科学家 通过在 NCI 赞助的临床试验和 NCI 临床试验网络中的领导地位，做出重大贡献 国家临床试验的开展、NCI临床试验在其机构的实施以及国家临床试验的开展 为 NCI 临床试验网络提供服务。 Brian Jonas 博士，医学博士、博士，是一位白血病专家，也是该系的副教授 加州大学戴维斯分校综合癌症中心 (UCDCCC) 的血液学/肿瘤学是一个活跃且高度活跃的学科。 加州大学戴维斯分校的专门临床科学家和试验师，他已将自己确立为开放临床领域的领导者 治疗 AML、MDS、急性淋巴细胞白血病 (ALL) 和其他血液恶性肿瘤的试验。 此外，他还获得了癌症临床试验部门令人垂涎的“最佳获得者”奖。 他的研究得到了他的转化研究的补充，涉及 AML 生物标志物、化疗敏感性和 作为 UCDCCC 的资产，他曾担任多个临床项目的 PI。 试验并作为临床试验管理的领导者，这包括主持 UCDCCC 血液学。 恶性肿瘤疾病小组委员会和 UCDCCC 数据和安全监测委员会。 除了在加州大学戴维斯分校的贡献外，乔纳斯博士还为多学科临床和转化做出了贡献 白血病委员会和西南肿瘤学组 (SWOG) 工作组等团队，以及 加州癌症联盟在 UCDCCC（国家临床试验中心）制定临床试验组合并为其提供信息 试验网络 (NCTN) 和实验治疗临床试验网络 (ET-CTN)。 作为通过 CTEP 项目组机制开发的两项 ECTCN 试验的国家主席 SWOG 是通过 NCTN 开发的 ECOG-ACRIN AML 试验的冠军。 UM1 联盟、加州癌症联盟 (CCC) 的参与者以及 CCC Heme 的成员 总体而言，Jonas 博士是 NCI R50 研究的合格临床科学家候选人。 专家奖，并在国家临床发展中表现出先前和持续的领导作用 试验、在 UCD 实施 NCI 赞助的临床试验，以及通过以下方式为 NCI 临床试验网络提供服务： 参与我们的 CCC 奖项将促进他的研究项目的持续发展和 提高他的机构和国家领导能力。